It may or may not be the end of the road for ranitidine medicines, but Indian companies affected by a suspension of these drugs by the European Medicines Agency and a withdrawal request by the US Food and Drugs Administration are taking different strategies to cope with continuing blows to the heartburn medicine that was a significant contributor to their revenues.
Taking different actions, active pharmaceutical ingredients manufacturer Solara Active Pharma Sciences is reassigning part of its capacity to manufacture other...




